European Archives - Page 288 of 1177 - European Medical Journal

Biomarkers for Breast Cancer Using Chromatin Imaging

Researchers have made a significant breakthrough in understanding ductal carcinoma in situ, a pre-invasive tumour that can progress to invasive breast cancer.

Breast Cancer Screening: Risks and Benefits

A new study projects outcomes of breast cancer screening strategies using digital breast tomosynthesis with or without supplemental breast magnetic resonance imaging.

Unmasking VEXAS: How Skin Clues Reveal a Hidden Genetic Disorder

Researchers found that skin involvement is a common and often early indicator of VEXAS syndrome, affecting 83% of patients.

Non-Athlete Sports Concussions Not Linked to Long-Term Cognitive Impairment

A study found that sports-related concussions had no long-term cognitive effects, while repeated non-sports-related concussions were linked to cognitive decline.

FLOW Trial Shows Benefit of Semaglutide in Type 2 Diabetes and CKD: EASD 2024

Findings from the FLOW trial, the first dedicated kidney outcomes trial with semaglutide in patients with Type 2 diabetes and chronic kidney disease, were presented at EASD 2024.

The Silent Killer: Spotlight on Sepsis

Ron Daniels, Founder and Executive Director of UK Sepsis Trust, debunks common myths around sepsis and discusses how to break barriers in diagnosis and treatment.

EMJ Respiratory 12 [Supplement 2] 2024

Today, asthma and COPD affect more than 550 million people worldwide, representing a huge and growing burden on patients, healthcare…

Transforming Asthma and COPD Care

Asthma and chronic obstructive pulmonary disease (COPD) affect more than 550 million people worldwide and are associated with substantial…

Predictors for Weight Loss and Glucose Control with Tirzepatide: EASD 2024

New analysis from the SURPASS-4 trial identifies crucial factors for maintaining blood glucose control and weight loss with tirzepatide in patients with Type 2 diabetes.

The ITP Treatment Landscape

In this video, discover updates in the treatment of immune thrombocytopaenia, with a focus on patient perspectives and unmet clinical needs.